California State Teachers Retirement System Has $973,000 Holdings in La Jolla Pharmaceutical (NASDAQ:LJPC)

California State Teachers Retirement System lowered its position in La Jolla Pharmaceutical (NASDAQ:LJPC) by 9.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,968 shares of the biopharmaceutical company’s stock after selling 3,027 shares during the period. California State Teachers Retirement System owned approximately 0.13% of La Jolla Pharmaceutical worth $973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Legal & General Group Plc lifted its stake in La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares during the last quarter. Nationwide Fund Advisors lifted its stake in La Jolla Pharmaceutical by 20.4% in the second quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 1,688 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in La Jolla Pharmaceutical by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 13,397 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 2,162 shares during the last quarter. Wells Fargo & Company MN lifted its stake in La Jolla Pharmaceutical by 23.0% in the second quarter. Wells Fargo & Company MN now owns 16,937 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 3,167 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in La Jolla Pharmaceutical by 21.2% in the second quarter. New York State Common Retirement Fund now owns 18,300 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 3,199 shares during the last quarter.

La Jolla Pharmaceutical (LJPC) opened at $32.01 on Tuesday. The stock has a market cap of $708.87, a P/E ratio of -6.28 and a beta of 1.20. La Jolla Pharmaceutical has a 1-year low of $16.71 and a 1-year high of $41.36.

In other La Jolla Pharmaceutical news, COO Jennifer Carver acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 27th. The shares were bought at an average cost of $33.22 per share, with a total value of $33,220.00. Following the completion of the acquisition, the chief operating officer now directly owns 4,500 shares in the company, valued at approximately $149,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Laura L. Douglass sold 10,000 shares of La Jolla Pharmaceutical stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $32.32, for a total transaction of $323,200.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $193,920. The disclosure for this sale can be found here. Company insiders own 25.47% of the company’s stock.

A number of equities analysts have recently commented on the stock. Jefferies Group lowered shares of La Jolla Pharmaceutical from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $40.00 to $29.00 in a research report on Monday. BidaskClub raised shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Friday. ValuEngine raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Chardan Capital raised their target price on shares of La Jolla Pharmaceutical from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, HC Wainwright raised their target price on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $57.00.

TRADEMARK VIOLATION NOTICE: “California State Teachers Retirement System Has $973,000 Holdings in La Jolla Pharmaceutical (NASDAQ:LJPC)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/california-state-teachers-retirement-system-sells-3027-shares-of-la-jolla-pharmaceutical-ljpc.html.

La Jolla Pharmaceutical Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply